Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer

  • Park, Sang Don (Department of Internal Medicine, Inha University College of Medicine) ;
  • Kim, Areum (Department of Internal Medicine, Inha University College of Medicine) ;
  • Park, Jin-Seok (Department of Internal Medicine, Inha University College of Medicine) ;
  • Shin, Chun Ho (Department of Internal Medicine, Inha University College of Medicine) ;
  • Nam, Hae Sung (Department of Internal Medicine, Inha University College of Medicine) ;
  • Kim, Lucia (Department of Pathology, Inha University College of Medicine) ;
  • Cho, Jae Wha (Department of Internal Medicine, Inha University College of Medicine) ;
  • Ryu, Jeong Sun (Department of Internal Medicine, Inha University College of Medicine) ;
  • Kwak, Seung Min (Department of Internal Medicine, Inha University College of Medicine)
  • Received : 2009.08.04
  • Accepted : 2009.09.24
  • Published : 2009.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Erlotinib ($Tarceva^{(R)}$) has been considered to be a new, promising oral chemotherapy agent for local advanced or metastatic non-small cell lung cancer (NSCLC). Erlotinib is regarded as relatively safe, but interstitial lung disease (ILD) related to erlotinib has been reported on an infrequent basis in Asia. We report an histologically confirmed case of recurrent erlotinib-induced ILD. Although, the patient was highly responsive to the first erlotinib treatment, the therapy was discontinued due to erlotinib-induced ILD. After intravenous high dose methylpredinisolone treatment, ILD was improved rapidly by radiologic studies, but the particular lung cancer re-emerged. We restarted the patient erlotinib on low-dose oral methylpredinisolone, resulting in a recurrence of erlotinib-induced ILD. Our case suggests that re-administration of erlotinib should be performed on a limited basis in patients that have developed ILD on previous use, even if a therapeutic effect can be estimated.

Keywords

References

  1. Johnson JR, Cohen M, Sridhara R, Chen Y, Williams GM, Duan J, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-21 https://doi.org/10.1158/1078-0432.CCR-05-0790
  2. Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 2008;112:2749-55 https://doi.org/10.1002/cncr.23490
  3. Kato T, Nishio K. Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. Respirology 2006;11:693-8 https://doi.org/10.1111/j.1440-1843.2006.00940.x
  4. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, et al. First-line single agent treatment with gefitinib in patients with advanced non- small-cell lung cancer: a phase II study. J Clin Oncol 2006;24:64-9 https://doi.org/10.1200/JCO.2005.02.5825
  5. Fukui T, Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg 2008;56:97-103 https://doi.org/10.1007/s11748-007-0193-8
  6. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, et al. Pulmonary toxicity associated with erlotinib. Chest 2007;132:1042-4 https://doi.org/10.1378/chest.07-0050
  7. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007;2: 537-43 https://doi.org/10.1097/JTO.0b013e318060d329
  8. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6 https://doi.org/10.1634/theoncologist.8-4-303
  9. Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007;7:150 https://doi.org/10.1186/1471-2407-7-150
  10. Kitajima H, Takahashi H, Harada K, Kanai A, Inomata S, Taniguchi H, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology 2006;11:217-20 https://doi.org/10.1111/j.1440-1843.2006.00835.x
  11. Suzuki M, Asahina H, Konishi J, Yamazaki K, Nishimura M. Recurrent gefitinib-induced interstitial lung disease. Intern Med 2008;47:533-6 https://doi.org/10.2169/internalmedicine.47.0737
  12. Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn J Clin Oncol 2006;36:269-73 https://doi.org/10.1093/jjco/hyl021

Cited by

  1. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight vol.68, pp.5, 2011, https://doi.org/10.1007/s00280-011-1737-2
  2. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature vol.75, pp.3, 2009, https://doi.org/10.1016/j.lungcan.2011.10.008